Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001193125-16-533048
Filing Date
2016-04-07
Accepted
2016-04-07 09:26:10
Documents
13

Document Format Files

Seq Description Document Type Size
1 424B4 d50169d424b4.htm 424B4 1550139
2 GRAPHIC g50169g29l67.jpg GRAPHIC 61768
3 GRAPHIC g50169g34b87.jpg GRAPHIC 94857
4 GRAPHIC g50169g49h48.jpg GRAPHIC 48664
5 GRAPHIC g50169g52g11.jpg GRAPHIC 56700
6 GRAPHIC g50169g53b75.jpg GRAPHIC 42738
7 GRAPHIC g50169g69b87.jpg GRAPHIC 53159
8 GRAPHIC g50169g73a33.jpg GRAPHIC 62271
9 GRAPHIC g50169g73u81.jpg GRAPHIC 138426
10 GRAPHIC g50169g89r58.jpg GRAPHIC 47764
11 GRAPHIC g50169g96s79.jpg GRAPHIC 96062
12 GRAPHIC g50169g98u17.jpg GRAPHIC 56070
13 GRAPHIC g50169g98x43.jpg GRAPHIC 73790
  Complete submission text file 0001193125-16-533048.txt   2699246
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-205001 | Film No.: 161558893
SIC: 2834 Pharmaceutical Preparations